Research graph
References from PTPN22 as a novel therapeutic target: a key intracellular checkpoint for NK cell therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/s41568-022-00491-0
10.1038/s41568-022-00491-0 · External reference
10.1182/blood.2022016200
10.1182/blood.2022016200 · External reference
10.1038/s41423-024-01145-x
10.1038/s41423-024-01145-x · External reference
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
10.1038/s41419-024-06438-7 · 2024 · External reference
10.1056/nejmoa1910607
10.1056/nejmoa1910607 · External reference
10.1038/s41591-023-02785-8
10.1038/s41591-023-02785-8 · External reference
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
10.1016/s0140-6736(24)02462-0 · 2025 · External reference
Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial
10.1038/s43018-025-00940-3 · 2025 · External reference
Breakthrough of solid tumor treatment: CAR-NK immunotherapy
10.1038/s41420-024-01815-9 · 2024 · External reference
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering
10.1126/sciadv.add6997 · 2023 · External reference
Inflammation and tumor progression: signaling pathways and targeted intervention
10.1038/s41392-021-00658-5 · 2021 · External reference
10.1038/nature01322
10.1038/nature01322 · External reference
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
10.1038/s41591-025-03532-x · 2025 · External reference
An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia
2023 · External reference
10.1182/blood.2023023529
10.1182/blood.2023023529 · External reference
10.1182/bloodadvances.2024014592
10.1182/bloodadvances.2024014592 · External reference
Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer
10.1038/s41467-022-35096-6 · 2022 · External reference
Impairment of NKG2D-Mediated Tumor Immunity by TGF-β
10.3389/fimmu.2019.02689 · 2019 · External reference
Mechanistic insights into IL-6-mediated NK cell dysfunction in NSCLC via the IRE1α-XBP1s-STAT3-UBE2S axis
10.1038/s41698-025-01140-z · 2025 · External reference
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
10.1126/scisignal.aad1884 · 2016 · External reference
NK Cell Exhaustion
10.3389/fimmu.2017.00760 · 2017 · External reference
10.1038/s41573-022-00618-w
10.1038/s41573-022-00618-w · External reference
10.1158/1078-0432.ccr-16-0934
10.1158/1078-0432.ccr-16-0934 · External reference
10.1146/annurev.iy.12.040194.000505
10.1146/annurev.iy.12.040194.000505 · External reference
SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells
10.1038/ncomms6108 · 2014 · External reference
10.4049/jimmunol.0900088
10.4049/jimmunol.0900088 · External reference
Shp-2 is critical for ERK and metabolic engagement downstream of IL-15 receptor in NK cells
10.1038/s41467-019-09431-3 · 2019 · External reference
Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy
10.1136/jitc-2020-001439 · 2020 · External reference
PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy
10.1080/17460441.2022.2084607 · 2022 · External reference
Systemic inhibition of PTPN22 augments anticancer immunity
10.1172/jci146950 · 2021 · External reference
10.1111/imm.12919
10.1111/imm.12919 · External reference
Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion
10.1136/jitc-2023-007614 · 2023 · External reference
Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
10.1016/j.omto.2022.10.011 · 2022 · External reference
CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells
10.1038/s41586-025-09087-8 · 2025 · External reference
10.1038/s41590-025-02103-z
10.1038/s41590-025-02103-z · External reference
Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling
10.1016/j.ccell.2025.05.011 · 2025 · External reference
10.1016/j.stem.2020.05.008
10.1016/j.stem.2020.05.008 · External reference
Optimization of Natural Killer Cell Expansion with K562-mbIL-18/-21 Feeder Cells and Assurance of Feeder Cell-free Products
10.3343/alm.2025.0168 · 2026 · External reference
Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis
10.1182/blood.2024025673 · 2025 · External reference
10.1093/nar/gkac959
10.1093/nar/gkac959 · External reference
10.1038/s41586-023-06816-9
10.1038/s41586-023-06816-9 · External reference
Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors
10.1158/2326-6066.cir-25-1229 · 2026 · External reference
10.1038/nchembio.916
10.1038/nchembio.916 · External reference
10.1111/j.1399-0039.2010.01512.x
10.1111/j.1399-0039.2010.01512.x · External reference
10.1038/s41591-018-0137-0
10.1038/s41591-018-0137-0 · External reference
10.1016/j.chembiol.2006.09.018
10.1016/j.chembiol.2006.09.018 · External reference
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
10.1186/s13045-022-01382-5 · 2022 · External reference
An autoimmunity-associated allele of PTPN22 enhances innate antiviral immunity to protect against acute coronavirus infection
10.1073/pnas.2519903123 · 2026 · External reference
IFN-γ–resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models
10.1126/scitranslmed.adp8166 · 2025 · External reference
Ablation of FAS confers allogeneic CD3- CAR T cells with resistance to rejection by T cells and natural killer cells
10.1038/s41551-024-01282-8 · 2024 · External reference
The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance
10.3389/fimmu.2022.947568 · 2022 · External reference
STAT3 directly regulates NKp46 transcription in NK cells of HBeAg-negative CHB patients
10.1002/jlb.2a1118-421r · 2019 · External reference
10.1182/blood-2014-03-564450
10.1182/blood-2014-03-564450 · External reference
10.1016/j.ymthe.2021.11.011
10.1016/j.ymthe.2021.11.011 · External reference
The clinical landscape of CAR NK cells
10.1186/s40164-025-00633-8 · 2025 · External reference
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances
10.1186/s40164-024-00583-7 · 2024 · External reference
